Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Egerton

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
NPJ Schizophrenia|August 3, 2019
Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamateKate Merritt, Rocio Perez-Iglesias, Kyra-Verena Sendt, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 4, 2021
Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomesGemma Modinos, Anja Richter, Alice Egerton, et al.
Schizophrenia Research|June 28, 2016
Adversity in childhood linked to elevated striatal dopamine function in adulthoodAlice Egerton, Lucia R Valmaggia, Oliver D Howes, et al.
Frontiers in Psychiatry|March 27, 2023
Parsing neurobiological heterogeneity of the clinical high-risk state for psychosis: A pseudo-continuous arterial spin labelling studyDominic Oliver, Cathy Davies, Fernando Zelaya, et al.
Schizophrenia Research|September 1, 2023
Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophreniaKira Griffiths, Sophie E Smart, Gareth J Barker, et al.
BMJ Open|November 26, 2021
Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA studyEdward Millgate, Eugenia Kravariti, Alice Egerton, et al.
Brain, Behavior, and Immunity|October 13, 2023
Changes in immunoglobulin levels during clozapine treatment in schizophreniaKira Griffiths, Maria Ruiz Mellado, Raymond Chung, et al.
Biological Psychiatry|February 4, 2021
Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode PsychosisThomas A Pollak, Angela Vincent, Conrad Iyegbe, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 12, 2014
Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosisAlice Egerton, James M Stone, Christopher A Chaddock, et al.
Schizophrenia Bulletin|January 5, 2021
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant SchizophreniaGrant McQueen, Kyra-Verena Sendt, Amy Gillespie, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
NPJ Schizophrenia|August 3, 2019
Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamateKate Merritt, Rocio Perez-Iglesias, Kyra-Verena Sendt, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 4, 2021
Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomesGemma Modinos, Anja Richter, Alice Egerton, et al.
Schizophrenia Research|June 28, 2016
Adversity in childhood linked to elevated striatal dopamine function in adulthoodAlice Egerton, Lucia R Valmaggia, Oliver D Howes, et al.
Frontiers in Psychiatry|March 27, 2023
Parsing neurobiological heterogeneity of the clinical high-risk state for psychosis: A pseudo-continuous arterial spin labelling studyDominic Oliver, Cathy Davies, Fernando Zelaya, et al.
Schizophrenia Research|September 1, 2023
Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophreniaKira Griffiths, Sophie E Smart, Gareth J Barker, et al.
BMJ Open|November 26, 2021
Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA studyEdward Millgate, Eugenia Kravariti, Alice Egerton, et al.
Brain, Behavior, and Immunity|October 13, 2023
Changes in immunoglobulin levels during clozapine treatment in schizophreniaKira Griffiths, Maria Ruiz Mellado, Raymond Chung, et al.
Biological Psychiatry|February 4, 2021
Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode PsychosisThomas A Pollak, Angela Vincent, Conrad Iyegbe, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 12, 2014
Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosisAlice Egerton, James M Stone, Christopher A Chaddock, et al.
Schizophrenia Bulletin|January 5, 2021
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant SchizophreniaGrant McQueen, Kyra-Verena Sendt, Amy Gillespie, et al.
Pageof 10